{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:19:34Z","timestamp":1778890774279,"version":"3.51.4"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adult T-cell \/lymphomaleukemia (ATLL) is caused by human T-cell lymphotropic virus type 1 (HTLV-1). Approximately 80% of ATLL patients develop humoral hypercalcemia of malignancy (HHM), a life-threatening complication leading to a poor prognosis. Parathyroid hormone\u2013related protein (PTHrP) and macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1) are important factors in the pathogenesis of HHM in ATLL and the expression of PTHrP can be activated by nuclear factor \u03baB (NF-\u03baB). NF-\u03baB is constitutively activated in ATLL cells and is essential for leukemogenesis including transformation of lymphocytes infected by HTLV-1. Our goal was to evaluate the effects of NF-\u03baB disruption by a proteasomal inhibitor (PS-341) and osteoclastic inhibition by zoledronic acid (Zol) on the development of ATLL and HHM using a novel bioluminescent mouse model. We found that PS-341 decreased cell viability, increased apoptosis, and down-regulated PTHrP expression in ATLL cells in vitro. To investigate the in vivo efficacy, nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mice were xenografted with ATLL cells and treated with vehicle control, PS-341, Zol, or a combination of PS-341 and Zol. Bioluminescent imaging and tumor cell count showed a significant reduction in tumor burden in mice from all treatment groups. All treatments also significantly reduced the plasma calcium concentrations. Zol treatment increased trabecular bone volume and decreased osteoclast parameters. PS-341 reduced PTHrP and MIP-1\u03b1 expression in tumor cells in vivo. Our results indicate that both PS-341 and Zol are effective treatments for ATLL and HHM, which are refractory to conventional therapy. [Cancer Res 2007;67(24):11859\u201366]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1701","type":"journal-article","created":{"date-parts":[[2007,12,18]],"date-time":"2007-12-18T13:52:12Z","timestamp":1197985932000},"page":"11859-11866","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Novel Bioluminescent Mouse Model and Effective Therapy for Adult T-Cell Leukemia\/Lymphoma"],"prefix":"10.1158","volume":"67","author":[{"given":"Sherry T.","family":"Shu","sequence":"first","affiliation":[{"name":"1Department of Veterinary Biosciences,"},{"name":"2Center for Retrovirus Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali V.P.","family":"Nadella","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"},{"name":"2Center for Retrovirus Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wessel P.","family":"Dirksen","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"},{"name":"2Center for Retrovirus Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad A.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"2Center for Retrovirus Research,"},{"name":"3Center for Biostatistics, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanda K.","family":"Thudi","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian L.","family":"Werbeck","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Lairmore","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"},{"name":"2Center for Retrovirus Research,"},{"name":"4Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Rosol","sequence":"additional","affiliation":[{"name":"1Department of Veterinary Biosciences,"},{"name":"2Center for Retrovirus Research,"},{"name":"4Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,12,18]]},"reference":[{"key":"2022061623232460800_B1","doi-asserted-by":"crossref","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A\u20081980; 77: 7415\u20139.","DOI":"10.1073\/pnas.77.12.7415"},{"key":"2022061623232460800_B2","doi-asserted-by":"crossref","unstructured":"Prager D, Rosenblatt JD, Ejima E. Hypercalcemia, parathyroid hormone-related protein expression and human T-cell leukemia virus infection. Leuk Lymphoma\u20081994; 14: 395\u2013400.","DOI":"10.3109\/10428199409049695"},{"key":"2022061623232460800_B3","doi-asserted-by":"crossref","unstructured":"Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy. Oncogene\u20082005; 24: 6047\u201357.","DOI":"10.1038\/sj.onc.1208979"},{"key":"2022061623232460800_B4","unstructured":"Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-\u03baB in primary adult T-cell leukemia cells. Blood\u20081999; 93: 2360\u20138."},{"key":"2022061623232460800_B5","doi-asserted-by":"crossref","unstructured":"Nadella MV, Dirksen WP, Nadella KS, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-\u03baB in adult T-cell leukemia\/lymphoma. Leukemia\u20082007; 21: 1752\u201362.","DOI":"10.1038\/sj.leu.2404798"},{"key":"2022061623232460800_B6","doi-asserted-by":"crossref","unstructured":"Richard V, Nadella MV, Green PL, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia\/lymphoma. Leukemia\u20082005; 19: 1175\u201383.","DOI":"10.1038\/sj.leu.2403787"},{"key":"2022061623232460800_B7","doi-asserted-by":"crossref","unstructured":"Grove M, Plumb M. C\/EBP, NF-\u03baB, c-ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1\u03b1 immediate-early gene. Mol Cell Biol\u20081993; 13: 5276\u201389.","DOI":"10.1128\/mcb.13.9.5276-5289.1993"},{"key":"2022061623232460800_B8","doi-asserted-by":"crossref","unstructured":"Tannir N, Riggs S, Velasquez W, Samaan N, Manning J. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer\u20081985; 55: 615\u20139.","DOI":"10.1002\/1097-0142(19850201)55:3<615::AID-CNCR2820550323>3.0.CO;2-X"},{"key":"2022061623232460800_B9","doi-asserted-by":"crossref","unstructured":"Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1\u03b1 induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res\u20082004; 19: 1105\u201311.","DOI":"10.1359\/JBMR.040314"},{"key":"2022061623232460800_B10","unstructured":"Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord\u20082000; 1: 253\u201363."},{"key":"2022061623232460800_B11","doi-asserted-by":"crossref","unstructured":"Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-\u03b1 is a potential osteoclast stimulatory factor in multiple myeloma. Blood\u20082000; 96: 671\u20135.","DOI":"10.1182\/blood.V96.2.671.014k24_671_675"},{"key":"2022061623232460800_B12","doi-asserted-by":"crossref","unstructured":"Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int\u20082005; 5: 18.","DOI":"10.1186\/1475-2867-5-18"},{"key":"2022061623232460800_B13","doi-asserted-by":"crossref","unstructured":"Dicato M, Boccadoro M, Cavenagh J, et al. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology\u20082007; 70: 474\u201382.","DOI":"10.1159\/000099284"},{"key":"2022061623232460800_B14","doi-asserted-by":"crossref","unstructured":"Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma. Oncogene\u20082005; 24: 419\u201330.","DOI":"10.1038\/sj.onc.1208212"},{"key":"2022061623232460800_B15","doi-asserted-by":"crossref","unstructured":"Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 tax transgenic mice and tax tumor transplants. Blood\u20082004; 104: 802\u20139.","DOI":"10.1182\/blood-2003-11-3967"},{"key":"2022061623232460800_B16","unstructured":"Fleisch H. Mechanisms of action of the bisphosphonates. Medicina (B Aires)\u20081997; 57 Suppl 1: 65\u201375."},{"key":"2022061623232460800_B17","doi-asserted-by":"crossref","unstructured":"Ishikawa C, Matsuda T, Okudaira T, et al. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol\u20082007; 136: 424\u201332.","DOI":"10.1111\/j.1365-2141.2006.06445.x"},{"key":"2022061623232460800_B18","doi-asserted-by":"crossref","unstructured":"Chuah C, Barnes DJ, Kwok M, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia\u20082005; 19: 1896\u2013904.","DOI":"10.1038\/sj.leu.2403949"},{"key":"2022061623232460800_B19","doi-asserted-by":"crossref","unstructured":"Gao L, Deng H, Zhao H, et al. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood\u20082005; 106: 4294\u2013302.","DOI":"10.1182\/blood-2005-04-1730"},{"key":"2022061623232460800_B20","doi-asserted-by":"crossref","unstructured":"Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene\u20082005; 24: 6005\u201315.","DOI":"10.1038\/sj.onc.1208974"},{"key":"2022061623232460800_B21","doi-asserted-by":"crossref","unstructured":"Feuer G, Zack JA, Harrington WJ, Jr., et al. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood\u20081993; 82: 722\u201331.","DOI":"10.1182\/blood.V82.3.722.722"},{"key":"2022061623232460800_B22","unstructured":"Richard V, Lairmore MD, Green PL, et al. Humoral hypercalcemia of malignancy: severe combined immunodeficient\/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am J Pathol\u20082001; 158: 2219\u201328."},{"key":"2022061623232460800_B23","doi-asserted-by":"crossref","unstructured":"Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis\u20082006; 23: 19\u201331.","DOI":"10.1007\/s10585-006-9008-z"},{"key":"2022061623232460800_B24","doi-asserted-by":"crossref","unstructured":"Richard V, Luchin A, Brena RM, Plass C, Rosol TJ. Quantitative evaluation of alternative promoter usage and 3\u2032 splice variants for parathyroid hormone-related protein by real-time reverse transcription-PCR. Clin Chem\u20082003; 49: 1398\u2013402.","DOI":"10.1373\/49.8.1398"},{"key":"2022061623232460800_B25","doi-asserted-by":"crossref","unstructured":"Holven KB, Damas JK, Yndestad A, et al. Chemokines in children with heterozygous familiar hypercholesterolemia: selective up-regulation of RANTES. Arterioscler Thromb Vasc Biol\u20082006; 26: 200\u20135.","DOI":"10.1161\/01.ATV.0000193619.67288.ed"},{"key":"2022061623232460800_B26","doi-asserted-by":"crossref","unstructured":"Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia\u20082004; 18: 1357\u201363.","DOI":"10.1038\/sj.leu.2403400"},{"key":"2022061623232460800_B27","doi-asserted-by":"crossref","unstructured":"Takaori-Kondo A, Imada K, Yamamoto I, et al. Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells. Blood\u20081998; 91: 4747\u201351.","DOI":"10.1182\/blood.V91.12.4747"},{"key":"2022061623232460800_B28","doi-asserted-by":"crossref","unstructured":"Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine\/paracrine and intracrine pathways. Regul Pept\u20082002; 105: 109\u201320.","DOI":"10.1016\/S0167-0115(02)00007-1"},{"key":"2022061623232460800_B29","doi-asserted-by":"crossref","unstructured":"Tovar Sepulveda VA, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology\u20082002; 143: 596\u2013606.","DOI":"10.1210\/endo.143.2.8645"},{"key":"2022061623232460800_B30","doi-asserted-by":"crossref","unstructured":"Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1\u03b1 on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood\u20082003; 102: 311\u20139.","DOI":"10.1182\/blood-2002-12-3905"},{"key":"2022061623232460800_B31","doi-asserted-by":"crossref","unstructured":"Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-\u03baB signaling pathway in Notch1-induced T-cell leukemia. Nat Med\u20082007; 13: 70\u20137.","DOI":"10.1038\/nm1524"},{"key":"2022061623232460800_B32","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res\u20082002; 62: 1083\u20136."},{"key":"2022061623232460800_B33","unstructured":"Yamaguchi K, Kiyokawa T, Watanabe T, et al. Increased serum levels of C-terminal parathyroid hormone-related protein in different diseases associated with HTLV-1 infection. Leukemia\u20081994; 8: 1708\u201311."},{"key":"2022061623232460800_B34","doi-asserted-by":"crossref","unstructured":"Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood\u20082007; 110: 334\u20138.","DOI":"10.1182\/blood-2006-11-059188"},{"key":"2022061623232460800_B35","doi-asserted-by":"crossref","unstructured":"Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-\u03baB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol\u20082006; 135: 688\u201392.","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"2022061623232460800_B36","doi-asserted-by":"crossref","unstructured":"Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood\u20082007; 110: 1098\u2013104.","DOI":"10.1182\/blood-2007-03-067710"},{"key":"2022061623232460800_B37","doi-asserted-by":"crossref","unstructured":"Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol\u20082001; 28: 35\u201344.","DOI":"10.1016\/S0093-7754(01)90263-5"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/24\/11859\/2578918\/11859.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/24\/11859\/2578918\/11859.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:21:21Z","timestamp":1655421681000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/24\/11859\/534067\/A-Novel-Bioluminescent-Mouse-Model-and-Effective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,15]]},"references-count":37,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2007,12,18]]},"published-print":{"date-parts":[[2007,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1701","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496767.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496767","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22371372","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371372.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,15]]}}}